TLSA
HealthcareTiziana Life Sciences Ltd
$1.53
$-0.07 (-4.38%)
Jan 5, 2026
Price History (1Y)
Analysis
Tiziana Life Sciences Ltd is a biotechnology company operating in the healthcare sector. With a market capitalization of $183.92M and 9 employees, the company falls within the medium scale for its industry. The company's financial health indicates significant losses with net income standing at -$12,841,000 and EBITDA at -$18,464,000 over the last four quarters. Gross margin, operating margin, and profit margin are all reported as 0.0%, indicating no profitability in these areas. The return on equity is -232.3% and the return on assets is -83.8%. The company's balance sheet shows $7.25M in cash and $107,000 in debt. Tiziana Life Sciences Ltd's valuation context features a forward P/E ratio of -7.69, indicating significant losses are expected to continue for the foreseeable future. The price to book ratio is 19.87, suggesting that investors value the company at nearly 20 times its book value.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
Visit website →Key Statistics
- Market Cap
- $183.92M
- P/E Ratio
- N/A
- 52-Week High
- $2.60
- 52-Week Low
- $0.63
- Avg Volume
- 311.63K
- Beta
- 0.25
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United Kingdom
- Employees
- 9